Johnson & Johnson’s Talvey and Tecvayli Combinations Show Significant Promise in Earlier Multiple Myeloma Treatment Lines

San Francisco, CA – Johnson & Johnson (J&J) has announced a significant stride forward in the treatment of multiple myeloma, a complex blood cancer. Recent Phase III trial results from the MonumenTAL-6 study demonstrate a marked improvement in progression-free survival (PFS) and overall survival (OS) when two of its innovative therapies, Talvey (talquetamab) and Tecvayli (teclistamab), are used in combination for patients with relapsed or refractory multiple myeloma. This pivotal research suggests these potent therapies could be integrated into earlier treatment lines, potentially revolutionizing care for a significant patient population.

n

The MonumenTAL-6 trial, a randomized, open-label, Phase III study (NCT06208150), evaluated two novel combination regimens against investigator’s choice of standard therapies in patients with relapsed or refractory multiple myeloma. The investigated combinations were:

n

n
• Tecvayli (teclistamab) and Talvey (talquetamab): This pairing leverages two of J&J’s bispecific antibody therapies, each targeting different antigens crucial for myeloma cell survival. Tecvayli targets B-cell maturation antigen (BCMA), a well-established target in multiple myeloma, while Talvey targets G-protein coupled receptor class C group 5 member D (GPRC5D), a novel target that has shown promise in overcoming resistance mechanisms.

n

• Talvey (talquetamab) and Pomalidomide: This combination pairs the GPRC5D-targeting Talvey with Pomalidomide, an immunomodulatory drug (IMiD) that has been a cornerstone of multiple myeloma treatment for years, particularly in later lines of therapy.

n

n

The results of the MonumenTAL-6 study have been met with considerable enthusiasm within the oncology community. Both investigational combinations demonstrated a statistically significant improvement in PFS compared to the investigator’s choice arm. Critically, patients receiving the Tecvayli-Talvey combination experienced an impressive 89% reduction in the risk of disease progression or death. The Talvey-pomalidomide combination also showed substantial efficacy, with a 73% reduction in the risk of progression or death.

n

Beyond PFS, the study also reported significant improvements in overall survival (OS). The Tecvayli-Talvey regimen emerged as the more impactful of the two tested combinations, with treated patients exhibiting a 62% reduction in the risk of death. These findings underscore the potential of these bispecific antibody combinations to not only control disease progression but also to extend patient lives.

n

A Closer Look at the MonumenTAL-6 Study Design and Objectives

n

The MonumenTAL-6 trial was meticulously designed to rigorously assess the efficacy and safety of these novel combination therapies in a challenging patient population. Patients enrolled in the study had relapsed or refractory multiple myeloma, meaning their cancer had returned or stopped responding to previous treatments. This group often faces limited therapeutic options and poorer prognoses.

n

The primary endpoint of the MonumenTAL-6 study was progression-free survival (PFS), a critical measure of treatment effectiveness that assesses the time a patient lives without their cancer worsening. Secondary endpoints included overall survival (OS), objective response rate (ORR), duration of response (DoR), and safety and tolerability profiles.

n

The decision to pit these investigational combinations against "investigator’s choice" reflects a common and robust trial design in oncology. This approach allows for a comparison against the best available standard of care as determined by the treating physician, providing a real-world benchmark for the new therapies.

n

The inclusion of both Tecvayli and Talvey in separate combinations highlights J&J’s strategy to explore the synergistic potential of its growing multiple myeloma pipeline. Tecvayli, a first-in-class BCMA-directed bispecific antibody, has already established its efficacy in later lines of therapy. Talvey, a GPRC5D-directed bispecific antibody, offers a novel mechanism of action that can overcome resistance to BCMA-targeted therapies. The combination of these two distinct targets is a rational approach to achieving deeper and more durable responses.

n

The inclusion of pomalidomide in one of the combinations also reflects an effort to integrate novel agents with established backbone therapies. Pomalidomide, an oral IMiD, has a well-documented safety and efficacy profile, and its combination with a bispecific antibody could potentially enhance overall response rates and deepen remissions.

n

Chronology of Development: From Approval to Phase III Triumph

n

The journey of Talvey and Tecvayli to this significant Phase III milestone has been marked by strategic development and regulatory approvals. Both therapies, developed by Janssen Biotech, Inc., a subsidiary of Johnson & Johnson, represent the cutting edge of immunotherapy in multiple myeloma.

n

n
• Tecvayli (teclistamab): This BCMA-directed bispecific antibody received its first regulatory approval in the United States from the Food and Drug Administration (FDA) in October 2022. Initially approved for adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, Tecvayli has demonstrated significant efficacy in a heavily pre-treated population. Its approval was based on data from the MajesTEC-1 study, which showed high response rates and durable remissions.

n

• Talvey (talquetamab): This GPRC5D-directed bispecific antibody followed closely, receiving FDA approval in August 2023. Talvey’s approval was for adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 antibody. The approval was supported by data from the MonumenTAL-1 study, which showcased remarkable response rates and sustained efficacy.

n

n

The MonumenTAL-6 study builds upon the success of these earlier trials and represents a critical step towards establishing these therapies in earlier treatment settings. The transition from later-line therapy to earlier lines is a common trajectory for successful oncology drugs, driven by the desire to intervene when the disease is less aggressive and patients have more treatment options. Positive Phase III data, like that from MonumenTAL-6, is the cornerstone for seeking expanded indications from regulatory bodies.

n

Supporting Data: Quantifying the Impact of Combination Therapies

n

The quantitative data emerging from the MonumenTAL-6 study provides a compelling picture of the impact of these novel combinations:

n

n
• Progression-Free Survival (PFS):n
  n
  • Tecvayli + Talvey arm: Risk of progression or death reduced by 89% compared to investigator’s choice.

  n

  • Talvey + Pomalidomide arm: Risk of progression or death reduced by 73% compared to investigator’s choice.

  n

n

• Overall Survival (OS):
  • Tecvayli + Talvey arm: 62% reduction in the risk of death compared to investigator’s choice.

These figures represent substantial improvements in patient outcomes. An 89% reduction in the risk of progression or death for the Tecvayli-Talvey arm is particularly noteworthy, indicating a profound impact on disease control. Similarly, a 62% reduction in the risk of death for the same arm suggests a significant survival benefit.

While specific data on objective response rates (ORR) and duration of response (DoR) for MonumenTAL-6 has not been fully detailed in the initial announcement, the significant improvements in PFS and OS strongly imply high response rates and durable remissions. This is consistent with the known activity of bispecific antibodies, which can induce deep and sustained responses by effectively engaging the immune system against cancer cells.

Safety Profile: A Familiar Landscape for Combination Therapies

A critical aspect of any new combination therapy is its safety profile. Johnson & Johnson has indicated that the safety profiles of both the Tecvayli-Talvey and Talvey-pomalidomide combinations closely mimic those observed with the individual monotherapies. While detailed safety data from the MonumenTAL-6 trial is still forthcoming, this statement is reassuring for clinicians and patients alike.

Bispecific antibodies, while highly effective, are associated with certain class-specific toxicities, most notably cytokine release syndrome (CRS) and neurological toxicities (ICANS – immune effector cell-associated neurotoxicity syndrome). Tecvayli and Talvey are known to carry these risks, as well as potential for cytopenias (low blood cell counts), including anemia and neutropenia.

The fact that the combinations did not appear to introduce significantly new or unexpected safety concerns is a testament to the careful development and management of these therapies. The clinical management of CRS, for instance, has evolved significantly, allowing for more effective intervention and mitigation of this potentially serious side effect.

Ajay Nooka, Director of the Myeloma Program at Emory University School of Medicine, commented on the significance of these findings, stating that the MonumenTAL-6 results add to a "growing body of evidence" supporting the early use of immunotherapy doublets. He highlighted their capacity to prompt "deep and durable responses" and improve outcomes across various practice settings. This expert endorsement further validates the clinical significance of J&J’s research.

The strong therapeutic potential of Talvey and Tecvayli in earlier disease lines has also been observed in other studies presented at the 2026 European Hematology Association (EHA) conference, suggesting a consistent trend of efficacy across different clinical settings.

Implications for the Multiple Myeloma Market and Future Treatment Paradigms

The positive Phase III readout from the MonumenTAL-6 study is a welcome development for Johnson & Johnson, poised to strengthen its competitive position in the highly dynamic multiple myeloma market. Currently, this landscape is significantly influenced by established players like Bristol Myers Squibb.

The implications of these results are far-reaching:

• Earlier Treatment Lines: The most immediate impact will be J&J’s pursuit of regulatory approval to move Talvey and Tecvayli into earlier lines of therapy. Currently, Talvey is approved in the fifth-line-plus setting in the US. A successful move to second-line treatment would dramatically expand its market potential and offer patients a highly effective option much earlier in their disease course. Tecvayli is already approved in the US in the second-line setting in combination with Darzalex Faspro (daratumumab, hyaluronidase-fihj) and as a monotherapy in the fifth line, making this new data particularly impactful for its combination potential.
• Market Disruption: GlobalData analysts have previously predicted that bispecific T-cell engagers (BiTEs) like Tecvayli and Talvey would significantly disrupt the relapsed/refractory multiple myeloma market. The MonumenTAL-6 results provide strong clinical evidence to support this prediction, potentially shifting treatment paradigms and market share.
• Competition with CAR-T Therapies: The multiple myeloma landscape is also seeing significant innovation with next-generation CAR-T therapies. For example, Gilead-owned Kite Pharma’s anitocabtagene-autoleucel is designed to enhance binding capacity and increase cytotoxicity. As CAR-Ts become more established, the success of bispecific antibodies in earlier lines will create a more complex and competitive treatment ecosystem.
• Emergence of In Vivo Cell Therapy: The field is also exploring the potential of in vivo cell therapy, where genetic modifications are made to immune cells within the patient’s body. Early studies, such as Kelonia Therapeutics’ Phase I inMMyCAR trial, are showing promising results, indicating another frontier in the fight against multiple myeloma.
• Strategic Portfolio Expansion: J&J’s success with these bispecific antibody combinations underscores their strategy of building a comprehensive portfolio in hematologic malignancies. The ability to combine therapies with different mechanisms of action, targeting distinct antigens, is crucial for overcoming drug resistance and achieving durable responses.

In conclusion, the MonumenTAL-6 trial results represent a significant advancement in the treatment of multiple myeloma. The demonstrated efficacy of Tecvayli and Talvey in combination, particularly their potential for earlier line use, offers new hope for patients and reshapes the competitive landscape. As Johnson & Johnson moves towards regulatory submissions, these findings are poised to redefine the treatment paradigm for this challenging blood cancer, offering the prospect of improved survival and quality of life for a growing number of patients.